Epstein-Barr virus latent membrane protein 2A exacerbates experimental autoimmune encephalomyelitis and enhances antigen presentation function

Rhoda A. Chang, Stephen D. Miller & Richard Longnecker

Department of Microbiology - Immunology, The Feinberg School of Medicine, Northwestern University, Chicago IL 60611.

Multiple sclerosis (MS) is an inflammatory, autoimmune disease of the central nervous system. The cause of MS is still unknown but epidemiological and immunological studies have implicated Epstein-Barr virus (EBV), which infects B cells, as a possible etiological agent involved in disease. Of particular interest is EBV latent membrane protein 2A (LMP2A) because previous studies have demonstrated that LMP2A enhances the expansion and differentiation of B cells upon antigen stimulation, revealing a potential contribution of this protein in autoimmunity. Since B cells are thought to contribute to MS, we examined the role of LMP2A in the animal model experimental autoimmune encephalomyelitis (EAE). In this model, transgenic mice in which B cells express LMP2A show increased severity and incidence of disease. This difference was not due to lymphocyte recruitment into the CNS or differences in T cell activation, rather, we show that LMP2A enhances antigen presentation function.

Results

LMP2A increases clinical symptoms of EAE. To determine whether the expression of LMP2A in B cells alters the development of EAE, transgenic LMP2A mice and litter mate controls (WT) were immunized with human recombinant myelin oligodendrocyte glycoprotein (rMOG) in CFA and monitored for clinical disease development. Human rMOG was used instead of MOG35–55 peptide because B cells were revealed to be important when immunizing with protein and not peptide, and with human rMOG and not rat rMOG.
scmce and chronic stages of EAE. Figure 2a demonstrates the flow cytometric gating strategy used to quantify total cells and lymphocyte subsets. We observed similar numbers of total infiltrating cells in brains (data not shown) and spinal cords of both LMP2A mice and litter mate controls (Figure 2b) as well as in the populations of CD3⁺CD4⁺, CD3⁺CD8⁺, and CD19⁺ cells (Figure 2c–e) at all three disease stages.

T Cell Activation in LMP2A transgenic mice and litter mate controls are similar. Due to the lack of differences found in the infiltrating cell populations between LMP2A mice and litter mate controls could explain the enhanced clinical symptoms of EAE, mononuclear cells were isolated from the CNS and quantified during the pre-clinical (days 7–9), peak (days 15–16), and chronic (days 22–24) stages of EAE. Figure 2a demonstrates the flow cytometric gating strategy used to quantify total cells and lymphocyte subsets. We observed similar numbers of total infiltrating cells in brains (data not shown) and spinal cords of both LMP2A mice and litter mate controls (Figure 2b) as well as in the populations of CD3⁺CD4⁺, CD3⁺CD8⁺, and CD19⁺ cells (Figure 2c–e) at all three disease stages.

To examine the cytokine profile of cells during EAE, splenocytes were collected at peak disease and restimulated with MOG35–55, an immunodominant determinant of MOG. The cytokine profiles in the culture supernatants were measured, demonstrating no difference in the levels of total MOG-specific IgG in serum collected from LMP2A mice and litter mate controls at pre-clinical, peak, and chronic stages of EAE. No differences in MOG-specific IgG between LMP2A mice and litter mate controls were detected at pre-clinical (Figure 4a), peak (data not shown), or chronic (data not shown) EAE. To examine if B cells from mice were secreting differential levels of IgG isotypes, cells from lymph nodes (Figure 4c–e) and spleens (Figure 4f–h) were collected at the pre-clinical, peak, and chronic stages of EAE and the number of MOG-specific IgG1, IgG2a, and IgG2b antibody secreting cells (ASCs) were assessed using an ELISPOT assay. The numbers of MOG-specific IgG2a and IgG2b secreting cells were similar in LMP2A mice and litter mate controls at all stages of EAE. However, in both lymph nodes and spleens, LMP2A mice had increased numbers of MOG-specific IgG1 secreting cells at the pre-clinical disease stage (Figure 4c, f). The number of ASCs between splenocytes and lymph node cells were similar. As support to the finding of increased numbers of IgG1-secreting cells at pre-clinical EAE, levels of MOG-specific IgG1 were increased in serum of mice at this stage of disease (Figure 4b).

Antigen presentation function is enhanced in LMP2A transgenic mice when compared to litter mate controls. Because LMP2A is known to enhance B cell activation13,16, we wanted to determine whether expression of LMP2A increased expression of MHC class II and co-stimulatory molecules in B cells. LMP2A mice were crossed with BCRMOG transgenic mice13. B cells from double transgenic (LMP2A-BCRMOG) and litter mate control mice (WT-BCR MOG) were isolated and cultured with T cells isolated from TCRMOG mice19 and MOG. Flow cytometric analysis revealed that culture with increased MOG resulted in increased expression of MHC class II, CD80, and CD86; however, increased expression of these proteins were similar on both LMP2A and litter mate control B cells (Figure 5a). Similarly, T cell activation markers CD25, CD44, CD62L, and CD69 were also analyzed on the co-cultured T cells and found to be expressed at control levels. (Figure 5b).

Since B cells are important professional antigen presenting cells (APCs), we next investigated whether the expression of LMP2A affected the antigen presenting function of B cells. Culture

| | WT | LMP2A |
|---|---|---|
| Incidence | 79% ± 9.7% | 92% ± 4.9% |
| EAE onset, day | 13.17 ± 1.48 | 13.05 ± 1.18 |
| Peak clinical score | 2.30 ± 0.38 | 2.71 ± 0.48 |
| Cumulative disease score | 23.33 | 31.43 |

EAE clinical parameters were observed in MOG-induced EAE in LMP2A and litter mate control (WT) mice. a–c. Each number represents the mean ± SEM of at least three independent experiments, each experiment including 3–6 WT and 5–10 LMP2A mice. d. Number represents the mean cumulative disease score of the representative disease course in Figure 1. Statistical difference of p = 0.0412 (*) for LMP2A mice versus litter mate controls is indicated.
of splenocytes with self-quenching DQ-OVA revealed no difference in antigen processing between control and LMP2A B cells (Figure 6a). However, the proliferation of MOG-specific T cells stimulated with rMOG in co-cultures with irradiated B cells from LMP2A-BCRMOG, as compared to B cells from WT-BCRMOG mice, was significantly enhanced (Figure 6b). This result was observed with two different concentrations of rMOG and at two timepoints, and reproducible with two separate preparations of rMOG protein.

To bypass processing of antigen, B cells from LMP2A-BCRMOG and WT-BCRMOG mice were cultured with MOG35–55-specific T cells.
in the presence of MOG35–55 peptide. LMP2A B cells stimulated increased T cell proliferation as compared to B cells of litter mate controls (Figure 6c). To investigate the need for processing of the MOG35–55 peptide, B cells were fixed with paraformaldehyde to prevent antigen processing but allow peptide loading. Cultures with fixed B cells from LMP2A-BCRMOG and WT-BCRMOG mice induced similar levels of T cell proliferation at two timepoints and three concentrations of antigen (Figure 6d). As expected, culture with rMOG protein and PFA-fixed B cells resulted in nominal T cell proliferation (data not shown). Collectively LMP2A B cells exhibit enhanced capacity to drive activation of naïve T cells.

Discussion

In the current study, we investigated if EBV LMP2A influences autoimmunity using EAE, an accepted murine model of MS. LMP2A is expressed in EBV latent infection and is known to alter normal B cell function. We found that clinical EAE scores were increased in LMP2A mice compared to litter mate controls. This enhancement was not due to do enhanced cell infiltration into the CNS or enhanced T cell activation despite the observation in in vitro models that LMP2A enhances cell migration. Interestingly, levels of IFN-γ-producing T cells and rMOG-specific IgG1 secreting cells were increased during the pre-clinical stage of disease. Most significantly, we found that LMP2A enhanced the APC function of B cells ex vivo, which may provide a mechanistic explanation for the contribution of EBV in autoimmune diseases such as MS. We suggest that increased autoreactive T cell activation as a result of LMP2A enhancement of B cell APC function promotes an inflammatory environment and facilitates disease progression during disease initiation. In addition, the increase in IFN-γ at pre-clinical EAE may also contribute to exacerbated disease. Following initiation of disease, the role of EBV LMP2A in altering other aspects of B cell function may be obscured by the robust T cell response, explaining the small differences in the pre-clinical stage of EAE and the modest difference in overall disease course.

The mechanism of how LMP2A enhances the antigen presenting function of B cells remains unknown, although many studies have revealed a role of LMP2A in altering signaling pathways leading to cell dysregulation. One possibility is that LMP2A enhances toll-like receptor (TLR) sensitivity of B cells, which could lead to enhanced APC function. Jiang et al. determined that TLR9 stimulation enhanced the APC function of B cells, and Wang et al. observed that LMP2A B cells were hypersensitive to TLR9 activation. TLRs, in particular TLR9, have already been implicated in EAE disease progression. Whether expression of LMP2A in B cells causes heightened sensitivities to TLR ligands in our model of EAE, and if those changes in sensitivity affect APC function remain interesting questions to address and is the focus of ongoing studies.
Also, despite the lack of differences in expression levels of MHC class II, CD80, and CD86 on B cells of LMP2A and litter mate controls, distribution and concentration of these molecules within lipid rafts, which has been shown to be important in the formation of immunological synapses, may be altered by LMP2A, resulting in enhanced T cell proliferation. The lack of difference between B cells of LMP2A and litter mate controls when PFA-fixed may be due to the loss of membrane fluidity, thereby disallowing LMP2A to enhance concentration or cross-linkage of BCR complexes.

Alternatively, LMP2A may be involved in the processing and presentation of antigen instead of the initial signaling of the BCR complex and synapse formation. In this case, LMP2A would play a role in the latter steps of antigen processing and presentation, as the endocytic pathway and initial cleavage of antigen is intact in LMP2A B cells.

Figure 5 | Levels of activation markers are similar between LMP2A transgenic mice and litter mate controls. T cells purified from TCRMOG mice and B cells purified from LMP2A-BCRMOG (LMP2A) and WT-BCRMOG control (WT) mice were co-cultured with the indicated concentrations of rMOG. Expression of MHCII, CD80, and CD86 on B220+ cells (a) and CD25, CD44, CD62L, and CD69 on CD3+ cells (b) were evaluated after 24 hour of culture using flow cytometry.

Figure 6 | Antigen presentation function is enhanced in LMP2A transgenic mice when compared to litter mate controls. a, Splenocytes from LMP2A and litter mate control mice (WT) were cultured with different concentrations of self-quenching DQ-OVA, and FITC signal was measured from CD19+ cells cultured at 37°C (solid lines) and 4°C (dotted lines). b–d, 3H-thymidine uptake by T cells purified from TCRMOG mice and B cells purified from LMP2A-BCRMOG (LMP2A) and WT-BCRMOG (WT) mice were measured after culturing with indicated concentrations of rMOG or MOG35–55 peptide. Cells were cultured for three (b) or four (c and d) days and pulsed with 3H-thymidine for the final 24 hours. Before culturing, B cells were irradiated (b and c) or fixed with paraformaldehyde (d). The data are representative of 2 (a), 5 (b), 3 (c), and 3 (d) independent experiments. Vertical bars represent mean ± SD between triplicate wells. Statistical differences of p<0.05 (*) or p<0.01 (**) are indicated.
cells, as demonstrated by the uptake of non-specific antigen DQ- OVA. The effect of LMP2A on antigen presentation and processing needs to be further explored, such as processing of protein, trimming of peptide, and transport through the Golgi apparatus.

Our initial observation of increased MOG-specific IgG1-secreting cells in spleens and lymph nodes of mice at the pre-clinical stage of disease was surprising due to the popular belief that EAE is considered a T<sub>H1</sub> mediated disease and knowing that cytokines produced by T<sub>TH2</sub> cells such as IL-4 promotes class switching to IgG1 isotypes. However, the presence of IgG1 during or after an inflammatory response has been reported: high titers of IgG1 autoantibodies are detected in the double-transgenic BCRMOG x TCRMOG mice that develop spontaneous optocric spinal encephalomyelitis despite a lack of increase in T<sub>TH2</sub> cytokines; the oligoklonal immunoglobulins found in the cerebral spinal fluid of MS patients are predominantly IgG1<sup>+</sup>. In our model, LMP2A B cells may encounter increased levels of MOG<sub>1-25</sub> pre-clinically, leading to IgG1 isotype switching. During the remainder of the disease course and with T<sub>TH1</sub> cytokines, however, B cells from LMP2A and litter mate controls could be encountering the same cytokines, leading to the observed equivalent levels of isotype switching to IgG1, IgG2a, and IgG2b.

Previous studies of LMP2A-transgenic mice also indicate a role for this protein in the initial stages of autoimmunity. LMP2A has been shown to bypass tolerance checkpoints<sup>37</sup> and enhance TLR sensitivity, as previously mentioned<sup>38</sup>. These characteristics or another factor due to enhanced B cell signaling<sup>39</sup> could lead to enhanced antigen processing and presentation. The contribution of latently infected B cells as antigen presenting cells may be significant in the context of MS, as myelin antigen would be limiting during the initiation of disease and B cells have been shown to be important antigen presenting cells when antigen is limiting.<sup>31,32</sup>

The contribution of EBV in MS remains controversial, and whether our results are reflective of the events in human disease remains unknown. While EBV remains persistently infected in only a small fraction of B cells in an individual<sup>40</sup>, all B cells in our transgenic mice express LMP2A<sup>40</sup>. Also, other viral proteins expressed during latency may affect the role of LMP2A in EAE and MS. These issues could begin to be addressed by adoptively transferring known ratios of B cells from LMP2A and litter mate controls into B cell deficient (μMT) mice, as well as using double transgenic mice which B cells express both LMP2A and other latency proteins.

Our finding that LMP2A enhances antigen presentation of B cells leads to a puzzling question of why EBV might enhance host cell APC function. Since mature, naïve B cells require encounter with antigen to survive, infection of these cells leads to a perplexing situation in which a balance between host cell survival and immune evasion must be maintained. While LMP2A enhances the survival of the host cell, other viral factors may be involved in regulating this effect. For example, gp42, a glycoprotein involved in EBV entry, binds MHC class II and thus interferes with presentation of peptide to T cells<sup>41</sup>. Investigating other EBV proteins in addition to LMP2A will delineate the individual and net effects of viral proteins on APC function. Alternatively, the effects of LMP2A on B cell APC function may be indirect. In response to LMP2A signaling, B cells may have evolved an anti-viral strategy by enhancing immune surveillance. Although B cells normally maintain a balance between immunodeficiency and autoimmunity, infection with EBV may tip the balance of B cells towards promoting autoimmunity.

In conclusion, we demonstrate that LMP2A enhances EAE severity and antibody production at the pre-clinical stage of disease. We also observed that this latency protein enhances B cell APC function. Collectively, these findings provide a novel potential mechanism to explain how latent EBV infection may contribute to autoimmune diseases, including MS. Further studies are required to definitively delineate the mechanism(s) by which LMP2A enhances antigen presentation and how this results in exacerbated disease.

**Methods**

**Mice**. LMP2A transgenic mice were created in a C57Bl/6 background as previously described<sup>42</sup> and C57Bl/6 (2D2) mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and have been previously described. MOG<sub>1-25</sub> (IgG1) mice were obtained from the Kuchroo laboratory (Harvard Medical School, Boston, MA). All mice were bred and housed under specific pathogen-free (SPF) conditions in the Center for Comparative Medicine, Northwestern University. All experiments were performed in accordance with institutional and NIH guidelines and approved by the Animal Care and Use Committee at Northwestern University.

**MOG peptide and protein**. Synthetic peptide MOG<sub>35-55</sub> (MEYVGWYRSPFSR/VHLRYNGK) was purchased from Genemed Synthesis (San Francisco, CA), E. coli DH5α bacteria expressing the extracellular 125 amino acid domain of human MOG proteins were obtained from the Rudole laboratory (Yale University School of Medicine, New Haven, CT) and the protein was purified as previously described. Briefly, the bacteria were grown in antibiotic-supplemented Luria-Bertani broth and induced to overexpress histidine-tagged MOG. The protein was then denatured, purified via Ni-NTA Agarose (QiaGen), then refolded.

**Induction and Evaluation of EAE**. Six- to eight-wk-old C57Bl/6 mice were used with 100 μg of an emulsion containing 100 μg of rMOG and 200 μg of Mycobacterium tuberculosis H37Ra (BD Biosciences, San Jose, CA) in 250 μl of Complete Freund’s Adjuvant (CFA). Mice were injected intraperitoneally with 100 μg of pertussis toxin (PTX) (List Biological Laboratories, Cambell, CA) on days 0 and 2 post-immunization. Clinical scores were given on a scale of 0 to 5 based on the following symptoms: 0 = healthy; 1 = limp tail; 2 = mild hind limb weakness; 3 = mild hind limb paralysis; 4 = moribund. Immunologic analyses were carried out at preclinical (days 7–9), peak (days 12–14), and chronic (days 22–24) stages of EAE.

**Cell Isolation**. Isolation of CNS-infiltrating mononuclear cells from the CNS was performed as similarly described<sup>43</sup>, by isolating brains and spinal cords from PBS-perfused mice and treating with a solution of 0.2% WxL/mL Liberase R1 (Roche Applied Science), 50 μg/ml DNase I, and 25 mM Hepes in balanced salt solution and flushed through wire screens to obtain single cell suspensions. Cells were washed in 5 mM EDTA-Hank’s balanced salt solution before a Percoll (Amersham, Piscaywau, NY) gradient was used to isolate mononuclear cells. For spleen and lymph node, tissues were dissociated through wire screens to obtain single cell suspensions. Red blood cells were lysed in 155 mM ammonium chloride. Cells were then filtered through 40 μm nylon mesh. For APC experiments, CD19<sup>+</sup> B cells (from LMP2A-BCRMOG and WT-BCRMOG mice) and T cells (from TCRMOG mice) were purified to approximately 90 to 95% purity via magnetic cell sorting (MACS) columns utilizing magnetic beads coated with antibodies specific for CD19 or CD4 (Miltenyi Biotec, Auburn, CA, USA). CD19<sup>+</sup> B cells were irradiated or fixed in 1% paraformaldehyde for 8 minutes at room temperature before 100,000 each of CD19<sup>+</sup> B cells and T cells were cultured.

**Peripheral In Vivo Antigen-Specific Proliferation Assay**. Spleens and lymph node tissues (cervical, axillary, brachial, and inguinal) were harvested and washed through wire screens. Spleen cells were applied to flat-bottomed 96-well plates (Thermo Scientific) coated with 0.25 μg/well rMOG and incubated for 1 hour at 37 °C after blocking with a solution of Phosphate Buffered Saline, 0.05% Tween-20, and 5% Bovine Serum Albumin (PBS-TBSA; 0.05%Tween-20, and 5% Bovine Serum Albumin (PBS-TBSA). 10 ng/well of polyclonal anti-mouse IgG antibody (eBioscience) or monoclonal anti-mouse IgG1 antibody (clone A85-1) (BD Biosciences) was incubated for 1 hour at 37 °C, 1:10,000 dilution of horseradish peroxidase-conjugated goat anti-rat IgG (Amersham Biosciences) for 30 min. at 37 °C, and finally TMB One Component HRP Microwell Substrate and 450 mM Liquid Stop Solution (BioFX) were each applied to the wells. Plates were washed with PBS between steps except before application of Stop Solution. A SpectraMax M2 Microplate Readers

**Flow cytometric analysis**. Single cell suspensions of spleen, lymph node, brain, and spinal cord tissue were stained with the following monoclonal anti-mouse antibodies: CD3ε (PE-Cy7), CD45 (APC), MHCII-I-A/I-J-1E (PE), CD38 (FITC), CD49d (APC-PE-Cy7), CD62L (APC), CD69 (FITC) from eBioscience (San Diego, CA), or CD4 (FITC), CD8α (APC-Cy7), CD19 (PE), R20 (PerCP), CD3 (PerCP), CD4 (PE) from BD Biosciences (San Jose, CA). 0.5 μl antibody was added per 500,000 cells and incubated at 4 °C for 30 minutes in 2% FBS-PBS. For APC experiments analyzing co-stimulatory molecules, cells were first incubated with LIVE/DEAD Fixable Violet Dead Cell Stain from Invitrogen (Carlsbad, CA) to exclude dead cells. Cells were analyzed using a FACSCanto II machine (BD Biosciences) and Flowjo software (TreeStar, Ashland, OR).

**Enzyme-linked immunosorbent assay (ELISA)**. For serum ELISA, serial dilutions of serum were applied to flat-bottomed 96-well plates (Thermo Scientific) coated with 0.25 μg/well rMOG and incubated for 1 hour at 37 °C after blocking with a solution of Phosphate Buffered Saline, 0.05% Tween-20, and 5% Bovine Serum Albumin (PBS-TBSA). 10 ng/well of polyclonal anti-mouse IgG antibody (eBioscience) or monoclonal anti-mouse IgG1 antibody (clone A85-1) (BD Biosciences) was incubated for 1 hour at 37 °C, 1:10,000 dilution of horseradish peroxidase-conjugated goat anti-rat IgG (Amersham Biosciences) for 30 min. at 37 °C, and finally TMB One Component HRP Microwell Substrate and 450 mM Liquid Stop Solution (BioFX) were each applied to the wells. Plates were washed with PBS between steps except before application of Stop Solution. A SpectraMax M2 Microplate Readers
(Molecular Devices Corporation, Sunnyvale, CA) was used to read the plates at a wavelength of 450 nm. For cytokine ELISA, supernatants from cultures were collected and analyzed via standard protocols for Cytometric Bead Array (CBA) (BD Biosciences).

**Enzyme-linked immuno-spot assay (ELISPOT).** 350 µl 0.45 µm PVDF Unifilter plates (Millipore, Billerica, MA) were coated with 0.4 µg/well purified antibody against IL-2 (donkey JES6-1A12, eBioscience) or IFN-γ (clone R4-6A2), or 0.25 µg/well rMOG and incubated overnight at 4°C. 500,000 erythrocyte-free cells per well were incubated in complete RPMI for 24 hrs. at 37°C with 5% CO2. For IL-2 and IFN-γ plates, 100 UM MOG23–35 were also added with the cells. After washing, biotinylated antibodies against the following proteins were applied: IL-2 (clone JES6-5H4, eBioscience), IFN-γ (clone XMG1.2, eBioscience), IgG1 (clone A85–1), IgG2a[µ] (clone 5.7), IgG2b (clone R12–3), and IgM (R6–60.2). The plates were then incubated with an alkaline phosphatase-conjugated anti-biotin antibody (Vector Labs, Burlingame, CA) for 1 hr. at 37°C and developed using AP Conjugate Substrate Kit (Bio-Rad Laboratories, Hercules, CA). Spots were counted on an ELISPot plate reader (Cellular Technologies Ltd., Shaker Heights, OH). All antibodies are from BD Biosciences unless indicated.

**Statistical Analysis.** Graphs are presented as mean ± standard error of the mean (SEM) or standard deviation (SD). Statistical analysis was performed with the GraphPad Prism 5.0. Differences between multiple independent experiments were determined with paired, 2-tailed Student’s t-test. Unpaired, 2-tailed Student’s t-test was used in Figure 3e and 4b. Two-way Anova was used in Figure 6b and 6c. P values less than 0.05 were considered significant (*); p values less than 0.01 were considered very significant (**).

1. Lunemann, J. D., Kamradt, T., Martin, R. & Munz, C. Epstein-barr virus: environmental trigger of multiple sclerosis? *J Virol* 81, 6777–6784 (2007).
2. Nkibi, B., Bonah, M. M., Khosravi, F. & Talebian, F. Role of B cells in pathogenesis of multiple sclerosis. *Int Rev Neurobiol* 79, 13–42 (2007).
3. Giovannoni, G. & Ebers, G. Multiple sclerosis: the environment and causation. *Curr Opin Neurol* 20, 261–268 (2007).
4. Thacker, E. L., Mirzaei, F. & Ascherio, A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. *Ann Neurol* 59, 499–503 (2006).
5. Cross, A. H., Trotter, J. L. & Lyons, J. B cells and antibodies in CNS demyelinating disease. *J Neuroimmunol* 112, 1–14 (2001).
6. Cross, A. H. MS: the return of the B cell. *Neurology* 54, 1214–1215 (2000).
7. Hemmer, B., Csepok, S., Nessler, S. & Sommer, N. Pathogenesis of multiple sclerosis an update on immunology. *Curr Opin Neurol* 15, 227–231 (2002).
8. Smith-Jensen, T. et al. Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. *Neurology* 54, 1227–1232 (2000).
9. Wolf, S. D., Dittel, B. N., Hardardottir, F. & Janeway, C. A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. *J Exp Med* 184, 2271–2276 (1996).
10. Lyons, J. A., Ramsbottom, M. J. & Cross, A. H. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. *Eur J Immunol* 32, 1905–1913 (2002).
11. Lyons, J. A., San, M., Happ, M. P. & Cross, A. H. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. *Eur J Immunol* 29, 3432–3439 (1999).
12. Merchant, M., Caldwell, R. G. & Longnecker, R. The LMP2A TATAM is essential for providing B cells with development and survival signals in vivo. *J Virol* 74, 9113–9124 (2000).
13. Swanson-Mungerson, M., Bulrema, R. & Longnecker, R. Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro. *J Virol* 80, 6764–6770 (2006).
14. Portis, T. & Longnecker, R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. *Oncogene* 23, 8619–8628 (2004).
15. Caldwell, R. G., Brown, R. C. & Longnecker, R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. *J Virol* 74, 1101–1113 (2000).
16. Caldwell, R. G., Brown, R. C. & Longnecker, R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. *J Virol* 74, 1101–1113 (2000).
17. Wang, H. et al. EBV latent membrane protein 2A induces autoreactive B cell activation and THR hypersensitivity. *J Immunol* 177, 2793–2802 (2001).
18. Oliver, A. R., Lyon, G. M. & Ruddle, N. H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. *J Immunol* 171, 462–468 (2003).
19. Litzbarsky, T. et al. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. *J Exp Med* 188, 169–180 (1998).
20. Bettefi, E. et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. *J Exp Med* 197, 1073–1081 (2003).